



Webinars Presents:

Living Well with Pulmonary Arterial Hypertension

Monday, November 28, 2016, 7 p.m. – 8 p.m. EST

Presenter:

Jamil Aboulhosn, MD

About the Webinar

Do you or a loved one have pulmonary arterial hypertension (PAH) or high blood pressure in your lungs? If so, you don't want to miss this webinar. Register today to hear Dr. Jamil Aboulhosn, ACHA cardiologist tell you why it occurs, what the consequences are, and what treatment options are available. Attend the webinar and learn how to live your life to the fullest.

REGISTER NOW:

<https://attendee.gotowebinar.com/register/314896110193387011>

About the Presenter

Dr. Jamil Aboulhosn is the Director of the Ahmanson/UCLA Adult Congenital Heart Disease Center and is a specialist in ACHD, pulmonary hypertension, and the interventional congenital cardiology. He is widely published in the area of pulmonary hypertension and congenital heart disease and treats a large population of patients with these conditions. He is chairman of the Global Research working group for the International Society of Adult Congenital Heart Disease. He is also on the writing committee for the American College of Cardiology/American Heart Association Guidelines on Adult Congenital Heart Disease and is vice-chair of the ACHA Medical Advisory Board. He also serves on the ACHA Program Accreditation Steering Committee.

About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA or visit www.achaheart.org.

This webinar was made possible in part by unrestricted educational grants from Actelion Pharmaceuticals US, Inc., and Gilead Sciences.